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RhoG is a member of the Rac-like subgroup of Rho GTPases and has been linked to a variety of different cellular
functions. Nevertheless, many aspects of RhoG upstream and downstream signaling remain unclear; in particular, few
extracellular stimuli that modulate RhoG activity have been identified. Here, we describe that stimulation of epithelial
cells with epidermal growth factor leads to strong and rapid activation of RhoG. Importantly, this rapid activation was not
observed with other growth factors tested. The kinetics of RhoG activation after epidermal growth factor (EGF) stimu-
lation parallel the previously described Rac1 activation. However, we show that both GTPases are activated indepen-
dently of one another. Kinase inhibition studies indicate that the rapid activation of RhoG and Rac1 after EGF treatment
requires the activity of the EGF receptor kinase, but neither phosphatidylinositol 3-kinase nor Src kinases. By using
nucleotide-free RhoG pull-down assays and small interfering RNA-mediated knockdown studies, we further show that
guanine-nucleotide exchange factors (GEFs) of the Vav family mediate EGF-induced rapid activation of RhoG. In
addition, we found that in certain cell types the recently described RhoG GEF PLEKHG6 can also contribute to the rapid
activation of RhoG after EGF stimulation. Finally, we present results that show that RhoG has functions in EGF-
stimulated cell migration and in regulating EGF receptor internalization.
INTRODUCTION
The family of Rho GTPases comprises 22 members that are
divided into five subgroups based on amino acid sequence
similarity (Wherlock and Mellor, 2002; Burridge and Wen-
nerberg, 2004). The discovery of their role in regulating actin
organization and focal adhesion dynamics was a hallmark in
understanding the importance of these molecules (Ridley
and Hall, 1992; Ridley et al., 1992). Rho GTPases are now
known to be involved in controlling a diverse set of cellular
functions, including cell migration, gene expression, endo-
cytosis, cell cycle progression, and differentiation (Jaffe and
Hall, 2005).
Rho GTPases are molecular switches, alternating between
an active guanosine triphosphate (GTP)-bound form and an
inactive guanosine diphosphate (GDP)-bound form. Down-
stream signaling from Rho GTPases occurs through effector
molecules which can specifically bind to the GTP-bound
form of the GTPase (Bishop and Hall, 2000). The activity
state of Rho GTPases is regulated by three classes of up-
stream regulatory proteins. Guanine-nucleotide exchange
factors (GEFs) promote the exchange of GDP for GTP,
thereby activating the Rho protein (Rossman et al., 2005).
Conversely, GTPase-activating proteins (GAPs) stimulate
the intrinsic GTPase activity of Rho GTPases promoting GTP
hydrolysis, thereby rendering the Rho proteins unable to
interact with downstream effectors (Moon and Zheng, 2003).
Guanine-nucleotide dissociation inhibitors (GDIs) are the
third class of regulators and they bind and sequester Rho
GTPases in the inactive form (Dovas and Couchman, 2005).
The number of different GEFs and GAPs greatly exceeds the
number of Rho GTPases (70 GEFs, 50 GAPs), and they
each have individual binding specificities for different Rho
GTPases. The mechanisms of how most Rho GEFs and GAPs
are regulated remain unknown.
RhoG is an evolutionarily conserved member of the Rac-like
subgroup of Rho GTPases, with homologues identified in
mammals, Drosophila, and Caenorhabditis elegans (Hakeda-Su-
zuki et al., 2002; Vigorito et al., 2004). Several cellular functions
have been associated with RhoG, including neurite outgrowth,
gene expression, apoptosis, macropinocytosis, and uptake of
apoptotic cells (Katoh et al., 2000; Murga et al., 2002; Vigorito et
al., 2003; deBakker et al., 2004; Ellerbroek et al., 2004; Yamaki et
al., 2007), and also several pathogenic bacteria exploit RhoG
function of the host cells during their infection cycle (Patel and
Galan, 2006; Roppenser et al., 2009). However, knowledge of
RhoG regulation remains obscure, because only a few GEFs for
RhoG have been described and no cellular RhoG GAPs are
currently known. Until now, intercellular adhesion molecule
(ICAM-1) and syndecan-4 are the only cell surface receptors
that were shown to modulate RhoG activity after their engage-
ment (van Buul et al., 2007; Elfenbein et al., 2009). However,
given the high degree of phylogenetic conservation of RhoG,
its broad expression pattern, and the diversity of RhoG func-
tions, it has to be assumed that other receptors are also mod-
ulating RhoG activation.
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Epidermal growth factor (EGF) receptor signaling in-
volves a complex network of pathways (Oda et al., 2005). On
ligand binding, the dimerized EGF receptor (EGFR) under-
goes a conformational shift that stimulates its intrinsic ki-
nase activity (Ferguson, 2008; Landau and Ben-Tal, 2008).
Autophosphorylation is a primary result and facilitates
binding of numerous proteins to phosphorylated residues
on the receptor, thereby initiating various downstream sig-
naling pathways. In addition, direct phosphorylation of tar-
get proteins by the EGFR also contributes to signaling. Major
signaling targets known to be initiated by EGFR activation
are Src-family kinases (Osherov and Levitzki, 1994), phos-
phatidylinositol 3-kinase (PI3K) (Rodrigues et al., 2000), mi-
togen-activated protein kinase (MAPK) (Sasaoka et al., 1994;
Jones et al., 1999), and several Rho GTPases. For example,
different mechanisms have been described for the activation
of Rac1 and cdc42 after EGF stimulation (Scita et al., 1999;
Marcoux and Vuori, 2003; Ray et al., 2007; Itoh et al., 2008).
In the present study, we looked for extracellular factors
that stimulate RhoG activity. We identified EGF as a strong
and rapid activator of RhoG, whereas other growth factors
were not. We focused our studies on the immediate activa-
tion of RhoG and its close homologue Rac1 within 30 s after
EGF stimulation. Surprisingly, at this early time point RhoG
and Rac1 activation occur independently of Src and PI3K
signaling, suggesting direct signaling from the activated
EGFR to the RhoG GEF(s). We found different GEFs to be
involved in EGF-induced RhoG activation in a cell type-
specific manner, including members of the Vav family, and
PLEKHG6, and that the composition of GEFs in a given cell
type dictates the morphological change induced by EGF
stimulation (dorsal ruffling vs. cell spreading). Furthermore,
we found that RhoG regulates EGF induced cell migration
and early EGF receptor internalization processes.
MATERIALS AND METHODS
RhoG and Rac1 Activity Assays
To measure endogenous levels of GTP-loaded RhoG and Rac1, we used
pull-down assays as described previously (van Buul et al., 2007). In brief, cells
were washed twice with ice-cold Tris-buffered saline (50 mM Tris, pH 7.4, 5
mM MgCl2, 150 mM NaCl) and then lysed in lysis buffer (50 mM Tris, pH 7.4,
10 mM MgCl2, 150 mM NaCl, 1% Triton X-100, 1 mM phenylmethylsulfonyl
fluoride (PMSF), and 10 g/ml each of aprotinin and leupeptin). After clear-
ing the lysates by centrifugation at 14,000  g for 5 min, protein concentra-
tions of the supernatants were determined, and equal amounts of total protein
were used to measure RhoG.GTP and Rac1.GTP. Therefore, the supernatants
were rotated for 30 min with glutathione-Sepharose beads (GE Healthcare,
Little Chalfont, Buckinghamshire, United Kingdom), which were loaded with
60–90 g of either glutathione transferase (GST)-ELMO (GST fusion protein
containing the full-length RhoG effector ELMO) or GST-Pak1-binding domain
(PBD). Subsequently the beads were washed four times in lysis buffer. Pull-
downs and lysates were then immunoblotted for RhoG or Rac1, respectively.
Reverse Transcription-Polymerase Chain Reaction
(RT-PCR)
For semiquantitative RT-PCR analysis of knockdown efficiency or expression of
PLEKHG6 and Src homology 3 domain-containing guanine nucleotide exchange
factor (SGEF), total RNA was isolated using TRIzol (Invitrogen, Carlsbad, CA)
reagent and reverse transcribed using the First-Strand cDNA synthesis kit (Roche
Diagnostics, Indianapolis, IN). PCR was done using the following primers: SGEF:
forward, 5-ATGGACGGCGAAAGCGAGGTG-3 and reverse, 5-CCAT-
CAAATGTTCCTTGTCCT-3; PLEKHG6: forward, 5-CCACCCTGGACCT-
GACGTCC-3 and reverse, 5-TCAGTGGCCAGCTTTCAGGAACAGAG-3; and
2-microglobulin: forward, 5-CTCGCGCTACTCTCTCTTTCTGG-3 and re-
verse, 5-GCTTACATCTCTCAATCCCACTTAA-3.
RhoG-Nucleotide-free Pull-Down Assays and
Immunoprecipitations (IPs)
To pull down cellular GEFs acting on RhoG, GST-RhoG-15A protein was
bacterially expressed and bound to glutathione-Sepharose beads. Cells were
lysed in nucleotide-free lysis buffer (150 mM NaCl, 20 mM HEPES, pH 7.6, 5
mM MgCl2, 1% Triton X-100, 1 mM PMSF, 1 mM ortho-vanadate, and 10
g/ml each of aprotinin and leupeptin). After clearing the lysates by centrif-
ugation at 14,000  g for 5 min, protein concentrations of the supernatants
were determined, and equal amounts of total protein were used for the pull
down (45 min at 4°C). Subsequently, the beads were washed three times in
nucleotide-free lysis buffer. To immunoprecipitate Vav2 or Vav3, cell lysates
were prepared as described above, but using IP lysis buffer (50 mM Tris, pH
7.4, 1 mM EDTA, 150 mM NaCl, 1% Triton X-100, 1 mM PMSF, 1 mM
ortho-vanadate, and 10 g/ml each of aprotinin and leupeptin). Antibody
binding was performed overnight at 4°C, followed by protein A-Sepharose
beads binding for 1 h and three wash steps.
Cells, Media, Transfection, and Growth Factor
Stimulation
HeLa, A431, and NIH-3T3 cells were obtained from the LCCC tissue culture
facility (University of North Carolina at Chapel Hill, Chapel Hill, NC). Hu-
man umbilical vein endothelial cells (HUVECs) were obtained from Lonza
Walkersville (Walkersville, MD). HeLa, A431, and NIH-3T3 cells were cul-
tured in DMEM (high glucose, glutamine; Invitrogen) supplemented with
10% fetal bovine serum (Sigma-Aldrich, St. Louis, MO) and antibiotics (In-
vitrogen). HUVECs were cultured in EBM-2 (Lonza Walkerville). For trans-
fection of plasmid DNA, FuGENE6 (Roche Diagnostics) was used according
to the manufacturer’s protocol. For transfection of small interfering RNAs
(siRNAs) into HeLa cells siQuest reagent (Mirus Bio, Madison, WI) was used
according to the manufacturer’s instructions. In brief, 1.5 ml of serum-free
media was mixed with 18 l of siQuest reagent and 11.25 l of a 20 M siRNA
stock solution. After 20 min incubation at room temperature, the complexes
were added to a 10 cm tissue culture dish (cell confluence, 50%), with 7.5 ml
of fresh media containing serum. Twenty-four hours after transfection, the
media were changed, and 48 h after transfection, the cells were split 1:2. The
cells were used for subsequent experiments between 72 and 96 h after trans-
fection.
For growth factor stimulation experiments, cells were initially starved in
DMEM/0.5% bovine serum albumin (BSA) (delipidated BSA; Sigma-Aldrich)
for 4 h. Subsequently, the media were replaced by DMEM/0.5% BSA supple-
mented with the corresponding growth factor at the indicated concentration.
Human recombinant EGF and VEGF were obtained from R&D Systems
(Minneapolis, MN), human recombinant platelet-derived growth factor
(PDGF) was obtained from Sigma-Aldrich. All growth factors were used at a
final concentration of 20 ng/ml unless otherwise indicated.
Antibodies, Reagents, Expression Plasmids, and siRNAs
The following antibodies were used: mouse anti-Rac1 (BD Biosciences, San
Jose, CA), mouse anti-tubulin (Sigma-Aldrich), rabbit anti-phospho-473-Akt,
rabbit anti-Akt, rabbit anti-phospho-418-Src, mouse anti-phospho-extracellu-
lar signal-regulated kinase (ERK)1/2, rabbit phospho-serine protein kinase C
(PKC) substrate (Cell Signaling Technology, Danvers, MA), mouse anti-green
fluorescent protein (GFP) (Roche Diagnostics), mouse anti-myc (clone 9E12),
rabbit anti-Vav2 (clone C64H2; Cell Signaling Technology), rabbit anti-Vav3
(Cell Signaling Technology), and mouse anti-phospho-tyrosine (clone 4G10).
The anti-RhoG antibody was described previously (Meller et al., 2008) and
was kindly provided by M. Schwartz (University of Virginia). The pEGFP-
Trio construct was a kind gift of Betty Eipper (University of Connecticut). To
express myc-PLEKHG6, the full-length sequence of human PLEKHG6 (clone
40035014; Open Biosystems, Huntsville, AL) was cloned into the pCMV-myc
vector. The following pharmacological inhibitors were used at the indicated
final concentrations, if not mentioned otherwise: LY294002 (Calbiochem, San
Diego, CA), 30 M; PP2 (Sigma-Aldrich), 10 M; SU6656 (Sigma-Aldrich), 2.5
M; AG1478 (Sigma-Aldrich), 10 M; Gö6983 (Calbiochem), 1.32 M; and
U0126 (Sigma-Aldrich), 10 M. All used siRNA duplexes targeting mR-
NAs or nontargeting control siRNAs were synthesized by Sigma-Aldrich
or Dharmacon RNA Technologies (Lafayette, CO) and sequences are in-
dicated in Table 1.
EGFR Internalization Assays
HeLa cells were plated in DMEM/10% fetal bovine serum on coverslips
coated with fibronectin (20 g/ml fibronectin in phosphate-buffered saline
[PBS]; 3  104 cells/well). After cell attachment, cells were starved for 4 h in
DMEM/0.5% BSA. The coverslips were then incubated for 1 h at 4°C in cold
PBS/Alexa-488-EGF (1 g/ml) and then transferred to 37°C with DMEM/
0.5% BSA for the indicated times (2–20 min). After washing twice with cold
PBS, noninternalized EGF-Alexa-488 was removed by washing once for 2 min
and once for 10 s with PBS/HCl, pH 2.1, before fixing the cells with 3.7%
formaldehyde. To quantify the magnitude of internalized EGF-Alexa-488 at a
certain time point, fluorescent micrographs were taken with a 63 objective
at multiple random positions of a coverslip. By using MetaMorph software
(Molecular Devices, Sunnyvale, CA), the integrated fluorescence of at least 20
cells per condition was measured, background subtracted, and averaged.
Wound Healing Assays
For wound healing assays, confluent HeLa cell cultures were starved for 4 h
in DMEM before scratching the monolayer with a micropipette tip. The cells
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were subsequently incubated in media with or without EGF for 18 h. Images
were taken at 0 and 18 h, and the migration speed of each cell front was
calculated: [ (width 18 h)  (width at 0 h) ]/2.
RESULTS
EGF Induces Rapid Activation of RhoG
To identify physiological stimuli that regulate RhoG signal-
ing, we tested a panel of growth factors and measured the
activity status of RhoG. In agreement with observations by
others (Meller et al., 2008), we did not observe RhoG activa-
tion in starved HeLa cells after serum treatment (Figure 1A).
We next treated NIH-3T3 fibroblasts with PDGF and
HUVECs with vascular endothelial growth factor (VEGF)
for 2 and 5 min, but neither of these stimuli resulted in
activation of RhoG (Figure 1, B and C). Both PDGF and
VEGF treatment did however activate Rac1 as observed
previously (Pandey et al., 2000; Stockton et al., 2004; Gavard
and Gutkind, 2006; Garrett et al., 2007). Interestingly, when
we treated starved HeLa cells with media containing phys-
iological concentrations of EGF (20 ng/ml) (Sigismund et al.,
2005), we found a strong increase in active RhoG levels
compared with cells treated with media lacking EGF (Figure
1D). Levels of active Rac1 also increased after EGF treat-
ment, as described previously (Dise et al., 2008).
To understand the kinetics of RhoG activation after EGF
stimulation, we measured levels of active RhoG in HeLa
cells at time points from 30 s to 10 min after EGF (20 ng/ml)
exposure. Interestingly, RhoG peak activation was observed
as early as 30 s after EGF treatment, whereupon its activity
began to decrease between 5 and 10 min. Rac1 activity
followed the same kinetics (Figure 2A) as also reported by
others in a different cell type (Patel et al., 2007). Equivalent
activation kinetics of RhoG and Rac1 occurred in experi-
ments using different concentrations of EGF (100 and 300
ng/ml; data not shown). We also observed RhoG activation
after 30 s of EGF treatment in a different cell line (A431;
Figure 2B), which showed that EGF-induced RhoG activa-
tion at 30 s is not limited to HeLa cells.
Because of the fast activation of RhoG and Rac1 by EGF
treatment (30 s) and to separate these events from later
(potentially secondary) activation of these GTPases, we
refer from here on to their activation at 30 s as the “rapid
activation.”
Rapid Activation of RhoG and Rac1 by EGF Is Not
Interdependent
Next, we sought to determine whether the rapid activation
of RhoG and Rac1 by EGF treatment depend on each other,
because cross-talk between different Rho GTPases has been
described previously, particularly in the context of Rac1
activation by RhoG (Hall, 1998; Katoh and Negishi, 2003).
First, we examined whether RhoG activation by EGF de-
pends on Rac1. HeLa cells were depleted of Rac1 by siRNA
transfection and active RhoG was measured after EGF stim-
ulation. As expected, we found that Rac1 depletion did not
alter the rapid activation of RhoG within 30 s of EGF treat-
ment (Figure 3A).
Rac1 can be regulated downstream of RhoG (Katoh and
Negishi, 2003). Indeed, we observed that the basal activity
level of Rac1 was significantly decreased when RhoG was
knocked down in unstimulated HeLa cells, compared with
cells that were transfected with control siRNA (Figure 3B).
However, when RhoG knockdown cells were treated with
EGF for 30 s, they still responded with rapid Rac1 activation
Table 1. siRNA sequences
Protein Antisense Sense
PLEKHG6 (#1) UAGCAGAUCAGUCAUGAUCdTdT GAUCAUGACUGAUCUGCUAdTdT







Figure 1. RhoG is activated after EGF stimulation but not by other
growth factors or serum. Serum-starved cells were treated with the
indicated growth factors or serum for 0, 2, and 5 min. Endogenous
RhoG and Rac1 activities were measured from total cell lysates by
pull-down assays by using GST-ELMO and GST-PBD, respectively.
(A) HeLa cells were treated with 20% serum. Confirmation that Src
and PI3K signaling occurred in responses to the serum treatment
was done by blotting total cell lysates for Src-PY418 and Akt-PS473.
(B) NIH-3T3 fibroblasts were treated with 20 ng/ml PDGF. (C)
HUVECs were treated with 20 ng/ml VEGF. (D) HeLa cells were
treated with EGF (20 ng/ml). Cellular responses in B, C, and D to
stimulation by the specific growth factors were measured by blot-
ting total cell lysates for phospho-tyrosine at the molecular weights
corresponding to the relevant receptor tyrosine kinases.
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to the same extent as control transfected cells (Figure 3B).
This demonstrates that basal activity of Rac1 is influenced by
RhoG, whereas rapid activation of Rac1 after EGF stimula-
tion is not. These data indicate that the rapid activation of
both RhoG and Rac1 occur independently and do not de-
pend on signaling cross-talk between each other.
Signaling Pathways Involved in EGF-mediated Activation
of RhoG
RhoG activation by EGF has not been described previously;
thus, we were interested in understanding the underlying
signaling pathways. To this end, we tested whether inhibi-
tion of key EGF-activated signaling pathways affected the
rapid activation of RhoG. By using the pharmacological inhib-
itors U0126 and Gö6976, we tested the involvement of mito-
gen-activated protein kinase kinase (MEK)1/2 and PKC,
respectively. EGF-stimulated rapid activation of RhoG and
Rac1 was not affected by these inhibitors when compared
with dimethyl sulfoxide-treated control cells (Figure 4, A
and B). Both Src and PI3K activity were described previously
to be involved in the activation of Rac1 in colon epithelial
cells after 3 min of EGF stimulation (Dise et al., 2008). There-
fore, we also measured how the inhibition of these kinases
affected the rapid activation of RhoG and Rac1. We found
that inhibition of PI3K activity by LY294002 did not signif-
icantly affect rapid RhoG and Rac1 activation 30 s after EGF
treatment (Figure 4C). Furthermore, we found that inhibi-
tion of Src-family kinases by the inhibitor SU6656 also did
not interfere with the rapid activation of both RhoG and
Rac1 (Figure 4D). An additional Src-inhibitor (PP2) yielded
the same result (Supplemental Figure S1). Finally, we tested
whether the activation of RhoG depends on the kinase ac-
Figure 2. EGF induces rapid activation of RhoG and
Rac1 in different cell types within seconds. Endogenous
levels of RhoG.GTP and Rac1.GTP were measured in
serum-starved HeLa cells (A) or A431 cells (B) after EGF
treatment (20 ng/ml) for the indicated times. The bar
graph summarizes multiple independent experiments
with HeLa cells (n  3; error bars represent SEM).
Figure 3. Rapid activation of RhoG and Rac1
after EGF treatment is not interdependent. (A
and B) HeLa cells were transfected with the
indicated siRNAs: Rac1-specific siRNA (A),
RhoG-specific siRNA (B), and control siRNA
(A and B). Rapid activation of RhoG or Rac1
after EGF treatment was measured using GST-
ELMO and GST-PBD pull-down assays, re-
spectively. The bar graphs summarize the re-
sults of multiple independent experiments
(n  3; error bars represent SEM). The asterisk
indicates a significant difference (p  0.05) in
basal Rac1 activity between nonstimulated
control siRNA and nonstimulated RhoG siRNA-
transfected cells.
T. Samson et al.
Molecular Biology of the Cell1632
tivity of the EGF-receptor (EGFR) itself. As expected, inhi-
bition of the kinase activity of the EGFR by the pharmaco-
logical inhibitor AG1478 abolished activation of both RhoG
and Rac1 after 30 s (Figure 4E). In summary, the only kinase
activity we found to be necessary for the rapid activation of
RhoG and Rac1 upon EGF stimulation was the intrinsic
activity of the EGFR itself.
Identification of GEFs Mediating the Rapid Activation of
RhoG
Next, we aimed to identify GEFs involved in the rapid
activation of RhoG after EGF stimulation. Only a limited
number of GEFs have been described that stimulate nucle-
otide exchange of RhoG. We first sought to test the involve-
ment of the RhoG GEF SGEF (Ellerbroek et al., 2004) in this
pathway by using a nucleotide-free RhoG pull-down assay
for detection of active GEFs (Garcia-Mata et al., 2006). RhoG-
15A is a nucleotide-free mutant with high affinity for acti-
vated RhoG GEFs (Wennerberg et al., 2002). We expressed
myc-SGEF in HeLa cells and performed a pull-down assay
with bacterial GST-RhoG-15A protein on lysates from un-
treated cells and from cells treated for 30 s with EGF. How-
ever, we did not detect any change in the affinity of myc-
SGEF for RhoG-15A after 30 s of EGF treatment (Figure 5A),
indicating that SGEF is not contributing to the rapid RhoG
activation. We further confirmed this result by knocking
down endogenous SGEF expression in HeLa cells. RT-PCR
analysis confirmed that endogenous expression of SGEF
mRNA was strongly decreased after transfection of SGEF
siRNAs (Figure 5B). In agreement with the nucleotide-free
pull-down assay, we still observed rapid activation of RhoG
when we transfected HeLa cells with siRNA targeting SGEF
(Figure 5C). Together, these results suggest that SGEF does
not play a role in the rapid activation of RhoG after EGF
treatment.
GEFs of the Vav family seemed to be other likely candi-
dates for the rapid activation, because they have been im-
plicated downstream of EGFR (Pandey et al., 2000; Zeng et
al., 2000). Vav2 and Vav3 are expressed in many different
cell types (Turner and Billadeau, 2002), and they are known
to activate Rac1 after EGF stimulation. To test whether en-
dogenous Vav2 or Vav3 become activated as RhoG-specific
GEFs after EGF stimulation, we again performed RhoG-15A
pull-down assays from untreated cells or from cells after 30 s
of EGF treatment. Interestingly, we found that binding of
both Vav2 and Vav3 to GST-RhoG-15A strongly increased
after 30 s of EGF stimulation, whereas binding to GST only
did not change (Figure 5D). This result strongly suggested
that Vav2 and Vav3 are mediating the rapid activation of
RhoG. To test this further, we knocked down endogenous
Figure 4. Effects of different kinase inhibitors on rapid activation of
RhoG and Rac1 after EGF treatment. Serum-starved HeLa cells were
stimulated with EGF for 30 s in the presence of different pharmaco-
logical inhibitors as indicated (pretreatment for 1 h). (A) MEK1/2
inhibitor, U0126 (10 nM). (B) PKC inhibitor, Gö6976 (1.32 M). (C)
PI3K inhibitor, LY294002 (30 nM). (D) Src-family kinase inhibitor,
SU6656 (2.5 nM). (E) EGFR kinase inhibitor, AG1478 (10 M). RhoG.
GTP and Rac1.GTP were measured by pull-down assays. The bar
graphs summarize multiple independent experiments (n  3; error bars
represent SEM). The asterisks indicate significant differences (p  0.05).
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expression of Vav2 and Vav3. Even though we observed
only minor effects on rapid activation of RhoG when Vav2 or
Vav3 were knocked down individually (Figure 5E), the si-
multaneous knockdown of both Vav2 and Vav3 abolished
the rapid activation of RhoG after EGF treatment (Figure
5F). Rapid activation of Rac1 showed a similar decrease in
activity as RhoG after Vav2/Vav3 single and double knock-
downs (Figure 5, E and F).
Vav2 and Vav3 were shown before to be activated by
tyrosine phosphorylation after EGF stimulation (Patel et al.,
2007). However, it had not been tested whether the fast
kinetics we observe for RhoG activation also can be ob-
served for Vav2/Vav3 phosphorylation. Different mecha-
nisms for Vav2 and Vav3 activation have been proposed,
some of these suggesting mechanisms other than tyrosine
phosphorylation directly via the EGFR (Marignani and Car-
penter, 2001; Tamas et al., 2003; Dise et al., 2008). Therefore,
we tested whether Vav2 and Vav3 are phosphorylated with
the same kinetics as we observed for RhoG activation. In-
deed, by immunoprecipitating Vav2 and Vav3 with specific
antibodies and blotting for phospho-tyrosine, we observed
phosphorylation of both proteins after 30 s of EGF stimula-
tion (Figure 6A), recapitulating the kinetics of RhoG and
Rac1 activation. Inhibition of the EGFR kinase abolished
Vav2/Vav3 phosphorylation, but this phosphorylation was
not prevented by inhibiting any other kinase activity we
tested (PI3K, src, MEK; Figure 6, B and C). Therefore, we
conclude that Vav2 and Vav3 jointly mediate the rapid
activation of both RhoG and Rac1 through their direct phos-
phorylation by the EGFR kinase.
Involvement of PLEKHG6 in Rapid Activation of RhoG in
A431 Cells
Recently, another GEF (PLEKHG6) was found to activate
RhoG and that EGF-induced macropinocytosis in A431 cells
depends on PLEKHG6 (D’Angelo et al., 2007). Because mac-
Figure 5. GEFs of the Vav family me-
diate rapid activation of RhoG and
Rac1. (A) HeLa cells overexpressing
myc-SGEF were lysed without stimula-
tion or after 30 s of EGF treatment (20
ng/ml). The fraction of active SGEF
was precipitated using GST-RhoG-15A
protein and revealed by Western blot-
ting. (B) Knockdown efficiency of SGEF
siRNA was tested by SGEF-specific RT-
PCR from control- and SGEF-siRNA–
transfected HeLa cells. RT-PCR of 2-
microglobulin RNA served as a control.
(C) HeLa cells were transfected 72 h
before EGF stimulation with control or
SGEF-specific siRNA. Rapid activation
of RhoG or Rac1 after 30 s of EGF treat-
ment was measured using ELMO- and
PBD-pull-down assays, respectively.
(D) Serum-starved HeLa cells were
lysed without any stimulus or after 30 s of EGF treatment (20 ng/ml) and activated RhoG-specific GEFs were precipitated using
GST-RhoG-15A protein. Immunoblots of the precipitates revealed that both Vav2 and Vav3 are rapidly activated in HeLa cells after EGF
stimulation (right). (E and F) Experimental conditions as in B; siRNAs: control, Vav2, and Vav3 (E); control, Vav2/Vav3 simultaneously (F).
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ropinocytosis is a known RhoG-mediated function, we won-
dered whether PLEKHG6 also contributes to rapid RhoG
activation in A431 cells in a cell type-specific manner. First,
we wanted to confirm that PLEKHG6 has in vivo GEF
specificity for RhoG. In agreement with results from
D’Angelo and coworkers, endogenous RhoG activity was
increased when myc-PLEKHG6 was expressed in HeLa cells
(Supplemental Figure S2). PLEKHG6 does not seem to be
ubiquitously expressed in all tissues and cell lines (D’Angelo
et al., 2007). RT-PCR analysis revealed that the amount of
endogenous PLEKHG6 mRNA in HeLa cells is low and
close to the detection threshold level, whereas mRNA for
PLEKHG6 is relatively abundant in A431 cells (Figure 7A).
We therefore considered that PLEKHG6 might be an addi-
tional GEF mediating the rapid activation of RhoG after EGF
stimulation in those cells in which it is expressed. siRNAs
targeting PLEKHG6 were transfected into HeLa and A431
cells. The PLEKHG6 siRNAs were shown to target PLE-
KHG6 RNA based on RT-PCR analysis of A431 cells trans-
fected with these siRNAs (Figure 7B). Strikingly, we ob-
served decreased RhoG activity after EGF stimulation in
PLKHG6-depleted A431 cells but not in HeLa cells (Figure
7C). Interestingly, knockdown of PLEKHG6 in A431 cells
only affected rapid RhoG activation after EGF stimulation
but did not change rapid Rac1 activation (Figure 7D). This
result is in agreement with the previously described speci-
ficity of PLEKHG6, which preferentially activates RhoG
(D’Angelo et al., 2007), and further implies that RhoG and
Rac1 are differentially regulated in A431 cells. We also tested
the influence of knockdown of the Vav family GEFs in A431
cells (Figure 7E). Transfection of siRNA directed against
Vav2/Vav3 decreased the levels of rapidly activated RhoG
in A431 cells. Interestingly, and again different from HeLa
cells, we could not detect Vav3 in A431 cells by Western
blotting (data not shown). Accordingly, when we performed
single knockdowns of Vav2 and Vav3 in A431 cells, we
found that Vav2 knockdown led to the same decrease in the
rapid activation of RhoG and Rac1 as the double knockdown
of Vav2/Vav3 in HeLa cells (Figure 7E). In summary, we
found that the composition of GEFs in A431 cells is different
from HeLa cells (PLEKHG6 and Vav2 vs. Vav2/Vav3) with
regard to the regulation of rapid RhoG and Rac1 activation
after EGF stimulation.
A431 cells are well known for the rapid formation of
dorsal ruffles after EGF treatment (Araki et al., 2007). Fur-
thermore, PLEKHG6 was shown previously to induce dorsal
ruffle formation when overexpressed in different mamma-
lian cells (D’Angelo et al., 2007). We therefore tested whether
RhoG and PLEKHG6 regulate EGF-induced dorsal ruffle
formation in A431 cells. siRNA-transfected A431 cells were
plated at subconfluent densities and serum-starved before
being stimulated with 20 ng/ml EGF. Differential interfer-
ence contrast (DIC) microscopy movies of single cells were
taken and later categorized for cells that form dorsal ruffles
(dorsal-ruffle phenotype; Figure 8A, top row) versus cells
that spread a large lamellipodium in multiple directions
(Rac-like phenotype; Figure 8A, bottom row). We found that
the majority of control siRNA-transfected cells (78  3.5%;
mean  SEM) responded to EGF treatment with the forma-
tion of dorsal ruffles (Figure 8B). Interestingly, when we
knocked down RhoG or PLEKHG6, the fraction of dorsal
ruffling cells significantly decreased, and increased numbers
of cells showed the Rac-like phenotype (RhoG siRNA, 39%
dorsal ruffling and 61% Rac-like phenotype, each 10.2%
SEM; PLEKHG6 siRNA, 52% dorsal ruffling and 48% Rac-
like phenotype, each 4.7% SEM). These results show that
RhoG and PLEKHG6 are necessary for dorsal ruffle forma-
tion in A431 cells after EGF stimulation. Furthermore, when
we analyzed A431 cells transfected with siRNA targeting
Vav2/Vav3, we observed significantly fewer cells with a
Rac-like phenotype, and more cells formed dorsal ruffles
(95% dorsal ruffling and 5% Rac-like phenotype, each 2.7%
SEM). Of note, the dorsal ruffles formed by cells transfected
with Vav2/Vav3 siRNA had an overall different morphol-
ogy compared with control cells, in that the dorsal protru-
sions seemed to extend directly from the dorsal surface of the
cell rather than from extended lamellipodia (data not shown).
Overall, these results indicate that PLEKHG6 is the critical
component that dictates the different EGF-induced re-
sponses of HeLa and A431 cells. To test whether PLEKHG6
is indeed a component that controls EGF-induced dorsal
ruffle formation, we attempted to change EGF-induced ruf-
fling behavior of HeLa cells, which usually do not form prom-
inent dorsal ruffles. Therefore, we expressed PLEKHG6 protein
at very low levels in HeLa cells. At this low expression level,
we did not observe formation of spontaneous dorsal ruffles
Figure 6. Rapid phosphorylation of Vav2 and Vav3 after EGF
stimulation. HeLa cells were stimulated with EGF (20 ng/ml) for the
indicated times. Immunoprecipitated Vav2 and Vav3 were blotted
for phospho-tryosine and Vav2 or Vav3, respectively. (A) Kinetics of
Vav2 and Vav3 phosphorylation after different times of EGF stim-
ulation. (B and C) Preceding EGF stimulation for 30 s, the cells were
treated for 1 h with pharmacological inhibitors for different kinases:
EGFR kinase inhibitor: AG1478 (10 nM); PI3K inhibitor, LY294002
(30 nM); MEK1/2 inhibitor, U0126 (10 nM); Src-family kinase inhib-
itor, SU6656 (2.5 nM).
EGF Stimulates Activation of RhoG
Vol. 21, May 1, 2010 1635
(Figure 8, C and D). Interestingly, after stimulating the cells
with EGF, we observed formation of dorsal ruffles of such
PLEKHG6 expressing HeLa cells, which were barely ob-
served in cells transfected with mCherry empty vector alone
(Figure 8, C and D).
In conclusion, multiple GEFs (Vav-GEFs and PLEKHG6)
are involved in EGF-induced RhoG activation in a cell type-
specific manner and dictate the resultant cellular phenotype.
RhoG Regulates EGF-induced Cell Migration and EGFR
Internalization
Recently, it was found that fibroblast growth factor (FGF)-
induced cell migration is regulated by RhoG, whereas RhoG
does not influence cell migration under nonstimulated con-
ditions (Meller et al., 2008; Elfenbein et al., 2009). Therefore,
we next tested whether EGF induced cell migration also
requires RhoG. Interestingly, in wound healing assays we
found that HeLa cells transfected with RhoG targeting
siRNAs migrated significantly slower compared with con-
trol transfected cells. In contrast, under nonstimulated con-
ditions, migration speed was not significantly changed (Fig-
ure 9, A and B). Importantly, the decrease in wound closure
in RhoG knocked down cells was not due to decreased cell
proliferation (Supplemental Figure S3). We showed earlier
that rapid activation of RhoG and Rac1 after EGF treatment
occurs independently of each other but that under non-
stimulated conditions baseline Rac1 activity is increased by
RhoG (Figure 3B). Because the wound healing assays ex-
tended over a long time (18 h), we wondered whether in
contrast to the rapid activation mechanism, Rac1 activity
after 18 h of EGF treatment is again influenced downstream
from RhoG, similar to the nonstimulated conditions. Inter-
estingly, we indeed found that after EGF treatment for 18 h,
Rac1 activity was significantly reduced in cells that have
been knocked down for RhoG (Figure 9C). This result sug-
gests that the observed RhoG knockdown-dependent de-
crease in EGF-induced cell migration occurs as a result of
decreased Rac1 activity.
Cell migration is a process occurring in the range of min-
utes to hours. Because we focused in this study mainly on
the rapid activation of RhoG within 30 s, we wondered
whether other cellular processes with faster kinetics are
influenced by the rapid activation of RhoG. Therefore, we
tested whether short-term EGF signaling to the nucleus by
MAPK signaling is affected by RhoG, Rac1, or their Vav
regulators. However, we could not detect differences in
pERK signaling after knockdown of RhoG, Rac1, or Vav2/3
(Supplemental Figure S4).
The process of EGF receptor internalization occurs very
rapidly after EGF stimulation and its regulation is important
for the precise control of EGF signaling (Carpenter, 2000).
Rho GTPases have been implicated in modulating the effi-
Figure 7. PLEKHG6 and Vav-family GEFs are involved in EGF stimulated RhoG activation in A431 cells. (A) RT-PCR analysis with primers
specific for PLEKHG6 was performed with total RNA samples from HeLa and A431 cells. RT-PCR of 2-microglobulin RNA served as a
control. (B) To confirm knockdown with the PLEKHG6 siRNAs, RT-PCR analysis with primers specific for PLEKHG6 was performed with
total RNA samples from A431 cells that have been transfected with control or one of two different PLEKHG6-specific siRNAs (PLEKHG6 #1,
PLEKHG6 #2). RT-PCR of 2-microglobulin RNA served as a control. (C) A431 cells and HeLa cells were transfected with control siRNA or
one of two different PLEKHG6-specific siRNAs (PLEKHG6 #1, PLEKHG6 #2). All cells were stimulated for 30 s with EGF before GST-ELMO
pull-down assays were performed. The bar graphs represent RhoG activity 30 s after EGF treatment in PLEKHG6 knockdown conditions
compared with siRNA controls (n  3; error bars represent SEM). The asterisk indicates significant differences compared with control
siRNA-transfected cells (p  0.05). (D and E) A431 cells were transfected with the indicated siRNAs: control, PLEKHG6 #2 (D); control, Vav2,
Vav3, and Vav2/Vav3 (E). Rapid activation of RhoG or Rac1 after 30 s EGF treatment was measured using GST-ELMO and GST-PBD
pull-down assays, respectively.
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ciency of EGFR internalization (Lamaze et al., 1996; Kaneko
et al., 2005). Therefore, we sought to determine whether
EGFR internalization after EGF stimulation is regulated by
RhoG and Rac1. EGFR internalization assays were per-
formed using HeLa cells and Alexa488-conjugated EGF.
Cells transfected with control siRNAs started to internalize
EGFR within the first 2 min after shifting the cells to 37°C,
and the amount of internalized EGFR continued to increase
over 10 min (Figure 10A). Interestingly, cells transfected
with siRNA against Rac1 or RhoG displayed a significantly
decreased amount of internalized EGFR at all times. Build-
ing on our previous results showing that Vav2 and Vav3 are
required for rapid activation of both RhoG and Rac1 in HeLa
cells, we asked whether EGFR internalization was also re-
duced when Vav2 and Vav3 were simultaneously depleted.
Knocking down Vav2 and Vav3 expression in HeLa cells
resulted in a delayed and reduced amount of internalized
EGFR (Figure 10B). We conclude that the activation of RhoG
Figure 8. RhoG and PLEKHG6 are required for dorsal ruffle formation in A431 cells after EGF stimulation. A431 cells were transfected with
control, RhoG-, or PLEKHG6-specific siRNAs. After 72 h, the cells were plated on fibronectin-coated coverslips (5 g/ml). After 4 h of serum
starvation, the cells were treated with 20 ng/ml EGF and DIC microscopy movies of individual cells were taken (10 s/frame; 480 s total).
Cellular ruffling responses showed either a “dorsal ruffling phenotype” (A, top row, arrowheads indicate dorsal ruffles, also shown enlarged
in the inset) or a “Rac-like ruffling phenotype” (A, bottom row). Bar, 20 m. (B) Quantification of the occurrence of dorsal-ruffle phenotype
versus Rac-like phenotype after transfecting the different siRNAs. Shown are averaged results from three independently performed
experiments. Asterisks indicate significant difference compared with control siRNA transfected cells (Student’s t test, p  0.05 and p  0.01,
respectively). (C) HeLa cells were transfected with low amounts of expression constructs for mCherry or mCherry-PLEKHG6 and analyzed
for dorsal ruffle formation after EGF treatment. Bars, 20 m. (D) Quantification of the frequency of EGF induced dorsal ruffle formation of
HeLa cells transfected with the indicated expression constructs. Shown are averaged results from three independently performed experi-
ments. Asterisks indicate significant differences (Student’s t test, p  0.001).
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and Rac1 after EGF stimulation by the GEFs Vav2 and Vav3
regulates internalization of the EGFR.
DISCUSSION
RhoG has been implicated in various cellular activities, in-
cluding phagocytosis, macropinocytosis, neurite outgrowth,
apoptosis, and regulation of gene expression (Katoh et al.,
2000; Murga et al., 2002; Vigorito et al., 2003; deBakker et al.,
2004; Ellerbroek et al., 2004). Due to the broad diversity of
these processes, which occur in a cell-type and tissue-spe-
cific manner, one would predict that multiple pathways
regulate RhoG activity. However, RhoG upstream and
downstream signaling pathways are to date poorly charac-
terized. Only a few RhoG downstream effectors have been
identified, such as the ELMO protein family, PI3K, phospho-
lipase D1, and kinectin (Katoh et al., 2000; Vignal et al., 2001;
Wennerberg et al., 2002; Yamaki et al., 2007). Regarding
upstream regulation, a small number of RhoG GEFs are
known (Vav proteins, SGEF, PLEKHG6, Trio, and Kalirin),
but not a single cellular GAP has been described (Schuebel et
al., 1998; Movilla and Bustelo, 1999; Blangy et al., 2000; May
et al., 2002; Ellerbroek et al., 2004).
Compared with other Rho GTPases, only a few extracel-
lular stimuli have been found to regulate RhoG activity.
These include the cross-linking of ICAM-1 receptors on en-
dothelial cells (van Buul et al., 2007) and syndecan-4 engage-
ment by FGF (Elfenbein et al., 2009). Our results presented
here reveal that EGF strongly activates RhoG (Figure 2A).
EGF is a prominent growth factor influencing the behavior
of many different tissues and cell types, including epithelial
cells, smooth muscle cells, endothelial cells, and neural pro-
genitor cells (Igura et al., 1996; Major and Keiser, 1997; Beier
et al., 2008; Bertrand-Duchesne et al., 2009; Schwindt et al.,
2009). Recently, FGF treatment of endothelial cells also was
described to result in RhoG activation (Elfenbein et al., 2009).
However, the kinetics of this differ strikingly from EGF-
induced RhoG activation: In response to FGF treatment,
RhoG activity peaks after 10 min, whereas the peak activa-
tion of RhoG in response to EGF is reached by 30 s (Figure
2A) and has returned almost to baseline levels by 10 min.
EGF-induced RhoG activation also differs mechanistically
from FGF-induced RhoG activation. Although EGF stimula-
tion leads to rapid RhoG activation by activating GEFs in a
PKC-independent manner (Figure 4B), syndecan-4 engage-
ment by FGF results in a release of RhoG from GDI-1 by
PKC-mediated phosphorylation of GDI-1 (Elfenbein et al.,
2009).
The observation that PDGF and VEGF did not stimulate
rapid RhoG activation was striking given that, like EGF,
both PDGF and VEGF induce Rac1 activation (Figure 1).
Previous work has shown that the tyrosine kinase receptors
for each of these growth factors activate the Vav family of
GEFs (Pandey et al., 2000; Garrett et al., 2007; Takahashi et al.,
2008). It was not expected that one growth factor would
stimulate the Vav GEFs to activate both Rac1 and RhoG but
that other growth factors would stimulate the same GEFs to
activate only Rac1. A possible explanation for the EGF-
specific activation of RhoG is the involvement of a receptor-
specific scaffold, which promotes coupling of Vav GEFs to
RhoG. Interestingly, after EGF and PDGF stimulation, 90%
of the activated signaling proteins are identical and only
10% are unique to each growth factor (Kratchmarova et al.,
2005). It will be interesting to look for the critical compo-
nent(s) mediating EGF-induced, but not PDGF- or VEGF-
induced, activation of RhoG. Similarly, it will be important
to identify other tyrosine kinase receptors that activate
RhoG.
Activation of Rac1 in response to EGF stimulation has
been studied previously (Liu and Burridge, 2000; Beier et al.,
2008; Dise et al., 2008; Itoh et al., 2008), and multiple different
GEFs have been shown to be involved, including members
of the Vav family, Tiam, Sos, and Asef (Scita et al., 1999;
Marcoux and Vuori, 2003; Ray et al., 2007; Itoh et al., 2008).
Figure 9. EGF-induced cell migration is regulated by RhoG. HeLa
cells were transfected with the indicated siRNAs. The cell monolay-
ers were starved before wounding and cultured with or without
EGF. (A) Representative images of wounds immediately after
wounding (0 h) or after 18 h. (B) Averaged migration speed of the
cell fronts calculated from 36 image sets per condition (0 h/18 h) as
described in Materials and Methods. Asterisks indicate significant
differences between control and RhoG siRNA-transfected cells (Stu-
dent’s t test, p  0.05). (C) Rac1 activity was determined in control
or RhoG siRNA-transfected HeLa cells that were exposed to EGF
containing media for 18 h. The bar graph on the right summarizes
three different experiments. Asterisks indicate significant differences
between control and RhoG siRNA-transfected cells (Student’s t test,
p  0.05).
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Even though no study has attempted to analyze comprehen-
sively all these GEFs simultaneously and their interplay, it
seems likely that Rac1 activation by EGF is controlled in a
cell type- and cell function-dependent manner through these
different GEFs. Our studies on RhoG activation after EGF
stimulation support this concept, because we found different
combinations of GEFs being involved in different epithelial
cell types. Certainly, due to different GTPase specificities,
this set of EGF-responsive RhoG GEFs (Vav2/Vav3 and
PLEKHG6) has to be different from those found for Rac1.
We did not observe any influence of PI3K and Src-family
kinase inhibition on either RhoG or Rac1 activation, and we
have identified only the kinase activity of the EGFR itself as
necessary for the rapid activation of RhoG and Rac1. This
suggests that the rapid activation of both RhoG and Rac1
results from direct phosphorylation of the Vav GEFs by the
EGFR kinase. Interestingly, the various studies implicating
PI3K, Src, or both, have examined Rac1 activation at later
times after EGF stimulation (Marignani and Carpenter, 2001;
Tamas et al., 2003; Dise et al., 2008).
At the outset of this work, we did not anticipate finding a
role for the GEF PLEKHG6 in the rapid activation of RhoG
in response to EGF stimulation. PLEKHG6 was described
previously as a GEF for RhoG, and to a lesser extent also for
Rac1 (D’Angelo et al., 2007). We showed that in A431 cells
PLEKHG6 together with Vav-family GEFs is involved in the
rapid activation of RhoG after EGF stimulation (Figure 7, D
and E), whereas EGF induced Rac1 activity is not influenced
by this GEF. Furthermore, PLEKHG6 seems to be a critical
factor that determines the cellular response after EGF treat-
ment. We could convert nondorsal-ruffling HeLa cells to
dorsally ruffling cells by expressing low levels of exogenous
PLEKHG6 and stimulating with EGF. D’Angelo and co-
workers found that PLEKHG6 acts as a scaffold, forming a
ternary complex consisting of Ezrin, PLEKHG6, and RhoG
(D’Angelo et al., 2007). Thus, it is possible that in addition to
its function as a RhoG GEF, PLEKHG6 might also serve to
localize RhoG to the plasma membrane, placing it in prox-
imity with the EGFR. Experiments with cells expressing
PLEKHG6 mutants that do not bind to Ezrin, but which
Figure 10. EGFR internalization is modulated by RhoG and Rac1. HeLa cells were transfected with the indicated siRNAs 72 h before the
experiment (A: RhoG or Rac1; B: Vav2/Vav3). After binding of EGF-Alexa488 (1 g/ml in PBS) for 1 h at 4°C to HeLa cells, EGFR
internalization was induced by shifting the temperature to 37°C for the indicated times. The integrated fluorescence intensities of multiple
cells from each transfection were measured and averaged. Error bars represent SEM. All measured time points were significantly different
from the control (p  0.001), except at 0 min.
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retain GEF activity, could further clarify the role of PLE-
KHG6 in the rapid activation of RhoG in response to EGF
stimulation.
EGF signaling affects many major cellular processes, in-
cluding proliferation, survival and migration. RhoG has
similarly been shown to contribute to the regulation of these
activities (Katoh et al., 2000; Murga et al., 2002; Katoh et al.,
2006; Yamaki et al., 2007; Elfenbein et al., 2009). Our results
demonstrate that initial RhoG activation after EGF stimula-
tion is followed by a rapid decline in activity (Figure 2A).
For the regulation of most of the above-mentioned functions,
this time course of RhoG activation seems to be too fast.
Even though we found differences in the migration behavior
of HeLa cells when RhoG was knocked down, this seemed to
be more due to reduced Rac1 effects resulting from cross-
talk between RhoG and Rac1. However, processes like dor-
sal ruffle formation and internalization of the EGFR occur
within the time frame of rapid activation. EGFR internaliza-
tion is an endocytic process and functional roles for Rho
GTPases in endocytic processes are well accepted (Qual-
mann and Mellor, 2003). We have found that knocking
down the expression of either RhoG or Rac1 decreases the
internalization of the EGFR after EGF stimulation. Simulta-
neous knockdown of Vav2 and Vav3 also decreases EGFR
endocytosis. Even though clathrin-mediated endocytosis
seems to be the major pathway of EGFR internalization,
clathrin-independent endocytosis also has been reported
(Osherov and Levitzki, 1994; Sigismund et al., 2005; Zhu et
al., 2005). Our experiments did not address which endocytic
entry route of EGFR is affected by knocking down RhoG or
Rac1, or their regulators Vav2/Vav3. Both these GTPases
and the Vav GEFs have been implicated in different endo-
cytotic pathways previously. For example, RhoG is known
to stimulate macropinocytosis and caveolar endocytosis
(Prieto-Sanchez et al., 2006), whereas clathrin-independent
interleukin-2 receptor internalization was shown to be stim-
ulated by Rac1 (Grassart et al., 2008). While this work was in
revision, B cell receptor internalization after agonist stimu-
lation was found to depend on Vav GEFs and Rac GTPases
(Malhotra et al., 2009). All these examples argue for clathrin-
independent mechanisms by which RhoG and Rac1 may
affect EGFR internalization. One possible link between RhoG
and Rac1 and multiple different endocytic mechanisms is the
RhoG and Rac1 effector phospholipase D1 (Wennerberg et
al., 2002), which was recently shown to stimulate EGFR
internalization by activating dynamin (Lee et al., 2006). De-
termining how RhoG and Rac1 regulate the internalization
route will be important, because it was recently suggested
that the fate of internalized EGFR (degradation vs. recycling)
is determined by the route of entry, more precisely, if it is
mediated via a clathrin-dependent or independent pathway
(Sigismund et al., 2008).
In summary, we demonstrate here that RhoG is rapidly
activated by EGF through GEFs of the Vav family and,
depending on the cell type, through the GEF PLEKHG6.
Importantly, the specific combination of available GEFs in a
given cell type determines the cellular response (i.e., spread-
ing vs. dorsal ruffling). Specifically, we observe that the
EGF-induced ruffling behavior changes when particular
GEFs are depleted or added. Functionally, we found that
RhoG contributes to EGF-stimulated cell migration in
wound healing assays and furthermore that both RhoG and
Rac1 and their regulators of the Vav family regulate early
dynamics of EGFR endocytosis. Future work is required to
clarify whether RhoG and Rac1 influence specific endocy-
totic entry routes of the EGFR (clathrin dependent or inde-
pendent).
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